Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00619671
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:23.604032+00:00
Published At
2013-01-16T00:00:00+00:00
Record Updated At
2013-01-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Refractory Myasthenia Gravis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2013-01-16"
protocolSection.identificationModule.nctId
"NCT00619671"
protocolSection.identificationModule.officialTitle
"Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis."
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Refractory Myasthenia Gravis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.